Loading
A phase 1/2 trial of Giredestrant and Abemaciclib in HR-positive / HER2-negative breast cancer, run by Genentech, Inc., now recruiting.
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer is a phase 1/2 interventional study registered as NCT07100106 by Genentech, Inc., with 285 participants planned, started 2025-10-07 and due to reach its primary completion in 2028-08-31. Interventions recorded: GDC-4198, Giredestrant and Abemaciclib.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Giredestrant, Flatiron Health (Roche), Abemaciclib, Endocrine therapy (SERMs, AIs, SERDs) and the tag pipeline.
Shares Giredestrant, Flatiron Health (Roche), Endocrine therapy (SERMs, AIs, SERDs) and the tag pipeline.
Shares Giredestrant, Flatiron Health (Roche), Endocrine therapy (SERMs, AIs, SERDs) and the tag pipeline.
Shares Giredestrant, Flatiron Health (Roche), Abemaciclib, UCSF Helen Diller Family Comprehensive Cancer Center and the tag pipeline.
Shares Giredestrant, Flatiron Health (Roche), Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares Abemaciclib, CDK4/6 inhibitors, UCSF Helen Diller Family Comprehensive Cancer Center, Endocrine therapy (SERMs, AIs, SERDs) and the tag pipeline.
Shares Abemaciclib, CDK4/6 inhibitors, Endocrine therapy (SERMs, AIs, SERDs) and the tag pipeline.
Shares Abemaciclib, CDK4/6 inhibitors, UCSF Helen Diller Family Comprehensive Cancer Center, HR-positive / HER2-negative breast cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/